S
Samjin Pharmaceutical Co Ltd
KRX:005500
Samjin Pharmaceutical Co Ltd
KRX:005500
Price:
20 350 KRW
0.49%
Market Closed
Updated:
Jun 15, 2024
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
This note will be permanently deleted.
Ask me anything about
Samjin Pharmaceutical Co Ltd
Balance Sheet
Balance Sheet Decomposition
Samjin Pharmaceutical Co Ltd
Samjin Pharmaceutical Co Ltd
| Current Assets | 148.1B |
| Cash & Short-Term Investments | 6.5B |
| Receivables | 57.1B |
| Other Current Assets | 84.5B |
| Non-Current Assets | 272.2B |
| Long-Term Investments | 57.9B |
| PP&E | 190.3B |
| Intangibles | 20.4B |
| Other Non-Current Assets | 3.6B |
| Current Liabilities | 153.9B |
| Accounts Payable | 15.9B |
| Accrued Liabilities | 7.1B |
| Short-Term Debt | 70B |
| Other Current Liabilities | 60.9B |
| Non-Current Liabilities | 8.1B |
| Long-Term Debt | 2.4B |
| Other Non-Current Liabilities | 5.7B |
Balance Sheet
Samjin Pharmaceutical Co Ltd
Samjin Pharmaceutical Co Ltd
Currency: KRW
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
2 693
|
886
|
11 910
|
21 914
|
30 699
|
31 896
|
18 910
|
7 941
|
2 341
|
2 401
|
|
| Cash |
293
|
381
|
342
|
330
|
199
|
31
|
50
|
34
|
86
|
58
|
|
| Cash Equivalents |
2 400
|
505
|
11 568
|
21 584
|
30 500
|
31 865
|
18 860
|
7 907
|
2 256
|
2 343
|
|
| Short-Term Investments |
3 500
|
3 890
|
7 120
|
6 500
|
4 655
|
5 390
|
5 580
|
3 770
|
2 321
|
1 605
|
|
| Total Receivables |
87 132
|
88 754
|
83 784
|
76 499
|
64 201
|
53 334
|
51 429
|
57 684
|
59 883
|
61 455
|
|
| Accounts Receivables |
86 860
|
88 598
|
83 733
|
76 390
|
64 071
|
53 222
|
51 414
|
56 791
|
59 838
|
60 131
|
|
| Other Receivables |
272
|
156
|
51
|
109
|
130
|
112
|
15
|
894
|
45
|
1 324
|
|
| Inventory |
33 933
|
43 054
|
42 312
|
51 437
|
61 724
|
58 032
|
70 065
|
69 709
|
68 595
|
79 603
|
|
| Other Current Assets |
1 106
|
625
|
713
|
921
|
2 232
|
1 459
|
876
|
768
|
1 128
|
1 117
|
|
| Total Current Assets |
128 365
|
137 209
|
145 839
|
157 271
|
163 511
|
150 110
|
146 860
|
139 872
|
134 268
|
146 180
|
|
| PP&E Net |
70 017
|
71 146
|
72 398
|
74 868
|
71 199
|
75 260
|
102 526
|
168 901
|
198 068
|
191 640
|
|
| PP&E Gross |
70 017
|
71 146
|
72 398
|
74 868
|
71 199
|
75 260
|
102 526
|
168 901
|
198 068
|
191 640
|
|
| Accumulated Depreciation |
41 485
|
47 987
|
54 864
|
58 413
|
61 215
|
56 321
|
74 457
|
79 485
|
88 226
|
102 881
|
|
| Intangible Assets |
2 870
|
3 949
|
3 923
|
3 970
|
4 237
|
7 518
|
8 496
|
10 313
|
10 340
|
20 300
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
634
|
784
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
7 189
|
7 736
|
4 610
|
4 666
|
10 298
|
9 431
|
8 031
|
10 333
|
63 329
|
58 065
|
|
| Other Long-Term Assets |
866
|
696
|
803
|
1 072
|
2 761
|
1 047
|
3 120
|
3 077
|
553
|
3 716
|
|
| Total Assets |
209 306
N/A
|
220 736
+5%
|
227 573
+3%
|
241 847
+6%
|
252 639
+4%
|
244 151
-3%
|
269 033
+10%
|
332 496
+24%
|
406 557
+22%
|
419 901
+3%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
16 150
|
15 546
|
20 507
|
21 422
|
17 947
|
15 667
|
12 710
|
12 236
|
13 180
|
11 137
|
|
| Accrued Liabilities |
2 920
|
4 015
|
4 118
|
4 058
|
3 974
|
3 645
|
3 238
|
4 990
|
7 281
|
7 960
|
|
| Short-Term Debt |
33 000
|
29 000
|
9 000
|
4 000
|
0
|
0
|
0
|
10 000
|
36 000
|
75 500
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
785
|
1 060
|
4 518
|
8 842
|
38 814
|
|
| Other Current Liabilities |
11 770
|
9 398
|
13 039
|
13 726
|
16 433
|
10 611
|
16 927
|
17 770
|
16 349
|
11 139
|
|
| Total Current Liabilities |
63 839
|
57 959
|
46 664
|
43 206
|
38 354
|
30 707
|
33 935
|
49 514
|
81 652
|
144 550
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
704
|
7 215
|
39 988
|
42 671
|
4 324
|
|
| Deferred Income Tax |
2 165
|
2 025
|
406
|
0
|
0
|
0
|
0
|
0
|
1 145
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
520
|
0
|
|
| Other Liabilities |
17 260
|
12 689
|
10 809
|
5 174
|
16 381
|
15 265
|
14 427
|
8 826
|
5 225
|
5 662
|
|
| Total Liabilities |
83 265
N/A
|
72 673
-13%
|
57 878
-20%
|
48 380
-16%
|
54 735
+13%
|
46 677
-15%
|
55 577
+19%
|
98 328
+77%
|
131 213
+33%
|
154 536
+18%
|
|
| Equity | |||||||||||
| Common Stock |
13 900
|
13 900
|
13 900
|
13 900
|
13 900
|
13 900
|
13 900
|
13 900
|
13 900
|
13 900
|
|
| Retained Earnings |
108 086
|
129 106
|
149 818
|
177 620
|
184 244
|
182 940
|
198 694
|
219 405
|
239 551
|
229 204
|
|
| Additional Paid In Capital |
25 866
|
26 721
|
27 593
|
28 440
|
29 246
|
30 013
|
23 877
|
23 877
|
23 877
|
23 877
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
3 087
|
3 087
|
3 087
|
3 087
|
3 087
|
7 273
|
|
| Treasury Stock |
21 884
|
21 773
|
21 737
|
26 628
|
26 557
|
26 476
|
21 631
|
21 631
|
13 762
|
23 754
|
|
| Other Equity |
74
|
109
|
121
|
136
|
158
|
184
|
1 703
|
1 703
|
14 865
|
14 865
|
|
| Total Equity |
126 042
N/A
|
148 063
+17%
|
169 695
+15%
|
193 467
+14%
|
197 904
+2%
|
197 474
0%
|
213 456
+8%
|
234 168
+10%
|
275 344
+18%
|
265 365
-4%
|
|
| Total Liabilities & Equity |
209 306
N/A
|
220 736
+5%
|
227 573
+3%
|
241 847
+6%
|
252 639
+4%
|
244 151
-3%
|
269 033
+10%
|
332 496
+24%
|
406 557
+22%
|
419 901
+3%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
13
|
13
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
